Verona Pharma plc — Major Shareholding Notification 2016

Aug 2, 2016

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 0344G

Verona Pharma PLC

02 August 2016

The following announcement replaces the notification Ref 9994F issued on 2 August 2016. The amendment is to Section 9 which should read as follows: The voting rights are managed and controlled by Edmond de Rothschild Investment Partners, acting in its capacity of management company of BioDiscovery 4 FPCI (not BioDiscovery 5 FPCI). All other details remain unchanged. The full amended text is shown below.

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii			Verona Pharma plc
2 Reason for the notification (please tick the appropriate box or boxes):
An acquisition or disposal of voting rights				x
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments
An event changing the breakdown of voting rights
Other (please specify):
3. Full name of person(s) subject to the notification obligation: iii		BioDiscovery 4 FPCI
4. Full name of shareholder(s) (if different from 3.):iv
5. Date of the transaction and date on which the threshold is crossed or reached: v		29 July 2016
6. Date on which issuer notified:		29 July 2016
7. Threshold(s) that is/are crossed or reached: vi, vii		0% to 4.3%

8. Notified details:
A: Voting rights attached to shares viii, ix
Class/type of shares if possible using the ISIN CODE	Situation previous to the triggering transaction						Resulting situation after the triggering transaction
Number of Shares			Number of Voting Rights			Number of shares		Number of voting rights			% of  voting rights x
Direct		Direct xi		Indirect xii	Direct			Indirect
Ordinary Shares	0			0			110,601,635		110,601,635			4.3%
B: Qualifying Financial Instruments
Resulting situation after the triggering transaction
Type of financial instrument			Expiration date xiii		Exercise/ Conversion Period xiv					Number of voting rights that may be acquired if the instrument is exercised/ converted.				% of voting rights
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi
Resulting situation after the triggering transaction
Type of financial instrument		Exercise price		Expiration date xvii		Exercise/ Conversion period xviii			Number of voting rights instrument refers to				% of voting rights xix, xx
													Nominal			Delta
Total (A+B+C)
Number of voting rights								Percentage of voting rights
110,601,635								4.3%

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: xxi
The voting rights are managed and controlled by Edmond de Rothschild Investment Partners, acting in its capacity of management company of BioDiscovery 4 FPCI.
Proxy Voting:
10. Name of the proxy holder:
11. Number of voting rights proxy holder will cease to hold:
12. Date on which proxy holder will cease to hold voting rights:
13. Additional information:	Figures are based on a total number of voting rights of 2,565,719,826 as per the Company's Result of General Meeting Announcement of 22 July 2016.
14. Contact name:	Naveed Siddiqi Andrei Buzdugan
15. Contact telephone number:	+33 698 661 203 +33 140 176 968

This information is provided by RNS

The company news service from the London Stock Exchange

END

HOLAKBDNQBKDNFK